BrunoCarneiro DeMedeirosMD

Clinical Trials

• Phase 2 Study of Temozolomide to Treat Poor Risk / Refractory Acute Myeloid Leukemia Start of enrollment: 2007 Dec 01

  Completed

  Phase 2

• Combination 5-azacitidine and Gemtuzumab Ozogamicin Therapy for Treatment of Relapsed Acute Myeloid Leukemia (AML) Start of enrollment: 2005 Jul 01

  Completed

  Phase 1, Phase 2

• Phase 1-2 of Azacitidine + Lenalidomide for Previously Untreated Elderly Patients With Acute Myeloid Leukemia (AML) Start of enrollment: 2009 Apr 01

  Completed

  Phase 1, Phase 2

• Vorinostat, Azacitidine, and Gemtuzumab Ozogamicin for Older Patients With Relapsed or Refractory AML Start of enrollment: 2009 May 01

  Completed

  Phase 1, Phase 2

• Phase II Study of VELCADE for Relapsed or Refractory T-cell Prolymphocytic Leukemia Start of enrollment: 2010 Jun 01

  Withdrawn

  Phase 2

• Safety & Efficacy Study of Oral Panobinostat (LBH589) With Chemotherapy in Patients < 65 Years Old With Acute Myeloid Leukemia (AML) Start of enrollment: 2010 Oct 01

  Completed

  Phase 1

• Single Agent Lenalidomide in Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia Start of enrollment: 2011 Jan 01

  Terminated

  Phase 2

• Azacitidine + Lenalidomide Combo in the Elderly With Previously Treated AML & High-Risk MDS Start of enrollment: 2011 Aug 01

  Terminated

  Phase 2

• Temozolomide Plus Vorinostat in Relapse/Refractory Acute Myeloid Leukemia (AML) Start of enrollment: 2013 May 01

  Completed

  Phase 2

• Analysis of Cutaneous and Hematologic Disorders by High-Throughput Nucleic Acid Sequencing Start of enrollment: 2011 Jun 01

  Terminated

• Phase III Study of CPX-351 Versus 7+3 in Patients 60-75 Years Old With Untreated High Risk (Secondary) Acute Myeloid Leukemia Start of enrollment: 2012 Dec 13

  Completed

  Phase 3

• Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia Start of enrollment: 2013 Feb 12

  Completed

  Phase 3

• Liposomal Cytarabine-Daunorubicin CPX-351 in Treating Patients With Untreated Myelodysplastic Syndrome or Acute Myeloid Leukemia Start of enrollment: 2013 May 07

  Completed

  Not Applicable

• Arsenic Trioxide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Start of enrollment: 2013 May 01

  Withdrawn

  Phase 2

• Decitabine and Midostaurin in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia Start of enrollment: 2013 Jun 01

  Terminated

  Phase 2

• Lenalidomide and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Start of enrollment: 2014 Feb 01

  Terminated

  Phase 1

• Safety and Efficacy Study of Pracinostat With Azacitadine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) Start of enrollment: 2013 Dec 24

  Completed

  Phase 2

• Feasibility and Outcomes of Allogeneic HCT Compared to Chemotherapy in Older AML Patients Start of enrollment: 2013 Jul 19

  Completed

• CPX-351 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Start of enrollment: 2014 Feb 03

  Completed

  Phase 2

• Ixazomib (MLN9708) in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Start of enrollment: 2014 Mar 01

  Terminated

  Phase 2

• MEK Inhibitor MEK162, Idarubicin, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Start of enrollment: 2014 Dec 01

  Terminated

  Phase 1

• Ibrutinib, Idarubicin and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Start of enrollment: 2016 Nov 01

  Terminated

  Phase 1

• Join now to see all